Skip to main content
. Author manuscript; available in PMC: 2016 Jun 27.
Published in final edited form as: J Liposome Res. 2015 Apr 13;26(1):47–56. doi: 10.3109/08982104.2015.1029494

Figure 2.

Figure 2

IR bevacizumab in BEV-ELIP fractions incubated at 25 °C in human plasma. (a) Absolute quantity of bevacizumab; (b) percent 0-time control. Black bars: supernate, no US; light gray bars: supernate, US; dark gray bars: pellet surface, no US; lightest bars: pellet surface, US. Bars=SE; n=3. *p<0.05 versus no US control.